6fk0
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Xray structure of domain-swapped cystatin E dimer== | |
+ | <StructureSection load='6fk0' size='340' side='right' caption='[[6fk0]], [[Resolution|resolution]] 2.90Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[6fk0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FK0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FK0 FirstGlance]. <br> | ||
+ | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fk0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fk0 OCA], [http://pdbe.org/6fk0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fk0 RCSB], [http://www.ebi.ac.uk/pdbsum/6fk0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fk0 ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Function == | ||
+ | [[http://www.uniprot.org/uniprot/CYTM_HUMAN CYTM_HUMAN]] Shows moderate inhibition of cathepsin B but is not active against cathepsin C. | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Protein activity is often regulated by altering the oligomerization state. One mechanism of multimerization involves domain swapping, wherein proteins exchange parts of their structures and thereby form long-lived dimers or multimers. Domain swapping has been specifically observed in amyloidogenic proteins, for example the cystatin superfamily of cysteine protease inhibitors. Cystatins are twin-headed inhibitors, simultaneously targeting the lysosomal cathepsins and legumain, with important roles in cancer progression and Alzheimer's disease. Although cystatin E is the most potent legumain inhibitor identified so far, nothing is known about its propensity to oligomerize. In this study we show that conformational destabilization of cystatin E leads to the formation of a domain-swapped dimer with increased conformational stability. This dimer was active as a legumain inhibitor by forming a trimeric complex. By contrast, the binding sites towards papain-like proteases were buried within the cystatin E dimer. We also showed that the dimers could further convert to amyloid fibrils. Unexpectedly, cystatin E amyloid fibrils contained functional protein, which inhibited both legumain and papain-like enzymes. Fibril formation was further regulated by glycosylation. We speculate that cystatin amyloid fibrils might serve as a binding platform to stabilize the pH-sensitive legumain and cathepsins in the extracellular environment, contributing to their physiological and pathological functions. | ||
- | + | Structural and functional analysis of cystatin E reveals enzymologically relevant dimer and amyloid fibril states.,Dall E, Hollerweger JC, Dahms SO, Cui H, Haussermann K, Brandstetter H J Biol Chem. 2018 Jul 2. pii: RA118.002154. doi: 10.1074/jbc.RA118.002154. PMID:29967063<ref>PMID:29967063</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
+ | <div class="pdbe-citations 6fk0" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Brandstetter, H]] | ||
+ | [[Category: Dall, E]] | ||
+ | [[Category: Amyloid fibril]] | ||
+ | [[Category: Cathepsin]] | ||
+ | [[Category: Cysteine protease]] | ||
+ | [[Category: Domain swapping]] | ||
+ | [[Category: Hydrolase inhibitor]] | ||
+ | [[Category: Inhibitor]] | ||
+ | [[Category: Legumain]] |
Revision as of 05:46, 11 July 2018
Xray structure of domain-swapped cystatin E dimer
|